Neuropsychiatric Disease and Treatment

Dovepress

open access to scientific and medical research

Open Access Full Text Article

CORRIGENDUM

Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease [Corrigendum]

Hager K, Baseman AS, Nye JS, Brashear HR, Han J, Sano M, Davis B, Richards HM. *Neuropsychiatr Dis Trea*. 2014;10:391–401.

On page 393, Figure 1, "Maintenance period (month 6 to 24)" should be "Maintenance period (month 4 to 24)"; "– Gal at stable dose (at least 18 mg/day) as achieved on day 84[c]" should be "– Gal at stable dose (at least 16 mg/day) as achieved on day 84[c]". The correct figure is shown below.



Notes: [a]Uptitration (from 16 mg/day to 24 mg/day) or downtitration (from 24 mg/day to 16 mg/day) of dose was allowed, based on tolerability and the investigator's judgment. Patients unable to tolerate a minimum of 16 mg/day dose were to discontinue treatment and were followed until the end of the maintenance and posttreatment period. The total number of patients included in the safety analysis set was n=2,045; [b]early study termination, per Data Safety Monitoring Board recommendation, when the prespecified number of deaths was ascertained and a significant imbalance favoring galantamine was observed; [c]a one-time dose titration to 16 or 24 mg/day was allowed, based on the investigator's judgment and patient tolerability.

Abbreviation: Gal, galantamine.